Align Technology (ALGN) Barclays 28th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 28th Annual Global Healthcare Conference summary
11 Mar, 2026Recent performance and market environment
Achieved 5% revenue growth and nearly 8% volume growth year-over-year, with broad-based stability across markets, including double-digit growth in DSOs, Latin America, APAC, and Europe.
Both teen and adult segments showed strong results, with teens up 7% and adults up 8%, supported by new product introductions and effective execution.
Exited a challenging year in a strong position, with improved results as the year progressed.
Stability in the operating environment is seen as key, with active conversion strategies and financing options helping drive patient adoption.
Macro factors like tax refunds and global events are monitored, but overall stability continues, with some economies showing notable growth.
Business drivers and growth strategies
Growth is balanced across ortho, GP, adult, and teen segments, with under-penetration in the teen market representing a significant opportunity.
Active conversion, local advertising, visualization tools, and financing are driving higher conversion rates, especially in DSOs.
Expansion in emerging markets like China, India, Brazil, and Turkey is contributing to growth, though at lower average selling prices (ASP).
Product and geographic mix are the main ASP drivers, with new doctors starting with simpler, high-margin cases.
DSOs represent about 25% of volume, with consolidation trends and partnerships (e.g., Smile Doctors, Heartland Dental) supporting further growth.
Competitive landscape and legal matters
Main competition remains traditional wires and brackets, though clear aligner competitors mostly compete on price and have recently raised prices.
Scale, technology, and brand are seen as key differentiators, with DSOs recognizing these advantages.
Ongoing litigation with Angel Aligner over patent infringement, with preliminary injunctions won in Europe and actions in the US and China.
Latest events from Align Technology
- Voting standard for Proposal 4 clarified; majority approval of shares present or represented required.ALGN
Proxy filing17 Apr 2026 - Record Q4 and FY2025 revenues, strong Clear Aligner and DSO growth, and positive 2026 outlook.ALGN
Q4 202517 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing7 Apr 2026 - Virtual Annual Meeting to address director elections, compensation, auditor, and bylaw proposals.ALGN
Proxy filing7 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing27 Mar 2026 - Strong growth in Europe and APAC, with product innovation and efficiency boosting margins.ALGN
Leerink Global Healthcare Conference 202610 Mar 2026 - Digital dentistry expansion, AI-driven innovation, and global growth drive strong financial outlook.ALGN
Investor Day 20253 Feb 2026 - Q2 2024 revenue up 2.6% to $1.03B; margin pressured by FX, mix, and legal settlement.ALGN
Q2 20243 Feb 2026 - Q1 2024 growth fueled by AI, 3D printing, and new digital orthodontic products.ALGN
The 44th Annual William Blair Growth Stock Conference31 Jan 2026